Patents are awarded to companies where TumorImagerTM is used:
Gilead Patent 20160075695 to Gilead for BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS Patent 20160075695
Body weights and tumor volume were monitored with a laser scan system, Biopticon Tumorimager (Biopticon), and recorded two times per week. Clinical signs were monitored daily during the dosing phase of the study. All animals were sacrificed by carbon dioxide exposure at designated time points.
Merck Patent 20140286946 to in 2014 Merck researches for METHOD FOR PREPARIN ANTIBODIES HAVING IMPROVED PROPERTIES Patent 20140286946
A week after implantation, the tumors were evaluated by 3-dimensional measurements using Biopticon Tumorlmager and randomized into treatment groups. Groups of five mice each were treated with indicated doses of antibodies in a weekly treatment regimen for 3 consecutive weeks.
Mallinckrodt LLC Patent 20140271820 to LIPOSOME OXALIPLATIN COMPOSITIONS FOR CANCER THERAPY Patent 20140271820
Tumor volume was determined using a tumor imaging system (Biopticon) 2-3 times per week. Body weights were measured weekly. Tumor volume data was analyzed to determine the ratio of treated versus control tumor volumes (%T/C).
The following cancer research institutions announced their services using TMS:
American Association for Cancer Research PDX tumor growth comparisons in immunodeficient mouse model
Mice were housed in Innovive individually vented cages and consumed Teklad Global Rodent Diet 2019 throughout the study. Tumors were measured multiple times per week using Biopticon’s TumorImager™. For all models except WHIM81, the tumors grew well and with very similar rate in both B-NDG and NSG™ mice.
American Association for Cancer Research, Covidien/Mallinckrodt Abstract 4400: Anti-tumor activity of liposomal docetaxel prodrug MNK-010 on PC3 human prostate xenografts in mice
The doses of Taxotere and MNK-010 were based on maximum tolerated dose (MTD) or highest dose tested for a given dose interval. Tumor volume was measured twice per week using the Biopticon tumor imaging system and tumor volume data was analyzed to determine tumor growth delay and partial tumor regression. Survival analysis was conducted and median survival time determined.
University of British Columbia BC Cancer Research Institute, Animal Resource Centre (BCCRI, ARC)
The Animal Resource Centre is a 20,000 sq ft barrier, with 18 animal holding rooms, and 9 procedure rooms. It continues to promote its imaging equipment including PET/CT, SPECT/CT, Maestro, and SARRP, as well as a Biopticon tumour imager (biopticon.com). We are looking forward to installing a new IVIS, shortly.
Changhua Christian Hospital, Department of Neurology, Taiwan, Republic of China Antitumor Actions of Intratumoral Delivery in Triple-Negative Breast Cancers
A control cohort received injections of the vehicle (MiR05 respiration buffer) and Pep-1 (1.9 mM). Each group had at least six transplant replicates. After 25 days of treatment, tumorigenesis was evaluated by analyzing the volumes of subcutaneous breast tumors in the mice by using a 3D laser scanning device (TumorImager; Biopticon Corporation, Princeton, NJ, USA) and measuring tumor weights.
Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo
Biweekly body weights and tumor volumes were recorded using a three-dimensional subcutaneous tumor scanning device (TumorImager; Biopticon, Princeton, NJ). At the termination of the study, mice were sacrificed by carbon dioxide asphyxiation. Mice were observed daily for clinical signs. Biweekly body weights and tumor volumes were recorded using a three-dimensional subcutaneous tumor scanning device (TumorImager; Biopticon, Princeton, NJ). At the termination of the study, mice were sacrificed by carbon dioxide asphyxiation.
University of Oklahoma Health Sciences Center Heparosan-coated liposomes for drug delivery
Tumor volume was measured every 5 days by a TumorImager (Biopticon Corporation; Princeton, NJ), an image acquisition and processing system that uses laser-scanning measurements to calculate more precise tumor volumes through algorithms. Mice were sacrificed 14 days after the third and final dose. Blood, tumor, and relevant organs (heart, liver, tumor, spleen, kidneys, lungs) were collected for further analysis.
Oklahoma University Health Sciences Center Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells
Mice were maintained on the Dox chow diet, and tumor growth was monitored using the Biopticon TumorImager. Mice were sacrificed approximately 5 weeks after injections, tumors were excised and dehydrated, and tumor weights were determined. Differences in shScramble and shTMEFF2-9 tumor weight were analyzed statistically by t test. n= 7.
Oklahoma Medical Research Center (OMRF) in Oklahoma OK
Drug efficacy studies – we evaluate in vivo efficacy of agents either alone or in combination with standard chemotherapy regimens against murine tumors, human tumor xenografts, and transgenic mouse models of human cancer. Tumor size is monitored by caliper measurements or TumorImager system allowing 3-D subcutaneous tumor scanning and/or in vivo imaging (for disseminated and orthotopic models). Tumor monitoring and Imaging – we monitor tumor growth and response to therapy using advanced tumor monitoring (Biopticon TumorImager, TumorManager systems) and imaging technology (IVIS Lumina III imaging system, Living Image, 4.0 Software).
University of Pennsylvania A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
Once tumor volume reached 70–100 mm3, animals (n = 50) were randomized using Tumor Manager (Biopticon) into 5 treatment groups: carboplatin (50 mg/kg i.p. injection weekly; Hospira); MK8776 (CHK1i, 50 mg/kg i.p. every 3 days; Selleckchem); AZD2281 (PARPi, 100 mg/kg oral gavage [OG] daily); AZD6738 (ATRi, 50 mg/kg OG daily; AstraZeneca); and vehicle. Tumor volume and body weight was measured every week.
University of Pennsylvania CCNE1 copy number is biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
For statistical power for in vivo studies, we transplanted 12 mice/arm.63,66 After randomization, once pre-specified tumor volume was achieved, there were approximately 10 mice/arm (range 4-12). Randomization was performed using Tumor Manager software (v 3.3.4, Biopticon). Mice that died for unknown reason (low tumor burden, normal weight and condition scores) were excluded from analysis.
University of Pennsylvania Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
After randomization, once pre-specified tumor volume was achieved, there were ~8 mice per arm (range 4–10). Randomization was performed using Tumor Manager software (v 3.3.4) by Biopticon. Mice that died for unknown reason (low tumor burden, normal weight, and condition scores) were excluded from analysis.
Gene Expression and Regulation Program, The Wistar Institute Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Once tumor volume reached 70–100 mm3, animals (n = 50) were randomized using Tumor Manager (Biopticon) into 5 treatment groups: carboplatin (50 mg/kg i.p. injection weekly; Hospira); MK8776 (CHK1i, 50 mg/kg i.p. every 3 days; Selleckchem); AZD2281 (PARPi, 100 mg/kg oral gavage [OG] daily); AZD6738 (ATRi, 50 mg/kg OG daily; AstraZeneca); and vehicle.
North-West University, Johannesburg, South Africa Establishment and Characterisation of Tumour Bearing Mouse Models for Evaluation of Biodistribution of a Radiopharmaceutical
Alternatively, a structured light scanner, which is a high-throughput system for measuring subcutaneous tumors, can be utilized. In comparison to conventional imaging techniques, the device is portable, less labour intensive and; does not require administration of radiolabelled tracers and anaesthesia (Girit et al., 2008).
